Status:
TERMINATED
Pharmacology of Aminophylline for Acute Kidney Injury in Neonates
Lead Sponsor:
Stanford University
Collaborating Sponsors:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Conditions:
Acute Kidney Injury
Eligibility:
All Genders
Up to 3 years
Brief Summary
Acute kidney injury (AKI) in critically ill neonates is common and associated with significant morbidity and mortality. No targeted therapeutic treatment strategies have been established for AKI in ne...
Eligibility Criteria
Inclusion
- Neonate \< 3 months post natal age
- Diagnosed with acute kidney injury (AKI)
- Receiving aminophylline for AKI treatment as per local standard of care.
Exclusion
- Presence of anatomical renal anomaly based on postnatal evaluation of the patient (hydronephrosis, multicystic kidney, renal agenesis, renal dysplasia, polycystic kidney, or obstructive uropathy)
- Patient on renal replacement therapy
- Major genetic abnormalities (trisomy 13, 18 or 21).
Key Trial Info
Start Date :
October 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2018
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT02276170
Start Date
October 1 2014
End Date
August 1 2018
Last Update
September 19 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Lucile Packard Children's Hospital Stanford
Palo Alto, California, United States, 94305-5208